Determination of Regulatory Review Period for Purposes of Patent Extension; DOJOLVI

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for DOJOLVI, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of patent extension applications to the US Patent and Trademark Office (USPTO), Department of Commerce.